Table 2.
Studies evaluating anogenital distance in women with polycystic ovary syndrome.
| Author | Year | Country | Study design | Number of patients enrolled | AGDAC and AGDAF (mm) | Outcome |
|---|---|---|---|---|---|---|
| Wu et al. (26) | 2017 | China | case–control | cases n = 156 controls n = 180 |
AGDAC: Cases: 104.9 (9.1) Controls: 97.1 (9.4) AGDAF: Cases: 26.6 (4.0) Controls: 22.0 (3.7) |
The presence of PCOS is associated with longer AGD. |
| Sánchez-Ferrer et al. (20, 21) | 2017 | Spain | case–control | cases n = 126 controls n = 159 |
AGDAC: Cases: 80.5 (11.3) Controls: 76.0 (10.4) AGDAF: Cases: 27.8 (5.7) Controls: 26.5 (5.1) |
Women with PCOS had significantly longer AGDAC and AGDAF compared to controls. |
| Hernández-Pen˜alver et al. (27) | 2018 | |||||
| Prieto-Sánchez et al. (28) | 2020 | |||||
| Simsir et al. (29) | 2019 | Turkey | prospective cohort | cases n = 65 controls n = 65 |
AGDAC: Cases: 101.0 (12.0) Controls: 98.0 (17.0) AGDAF: Cases: 23.0 (6.0) Controls: 21.0 (5.0) |
AGD in adult PCOS patients was longer than control PCOS patients. |
| Peters et al. (24) | 2020 | the Netherlands | case–control | cases n = 43 controls n = 43 |
AGDAC: Cases: 113.8 (16.9) Controls: 111.4 (13.7) AGDAF: Cases: 22.0 (5.8) Controls: 21.7 (6.2) |
The AGDAC was significantly different between groups, with an increased AGDAC in women with PCOS. |